Cargando…
CD271 activation prevents low to high-risk progression of cutaneous squamous cell carcinoma and improves therapy outcomes
BACKGROUND: Cutaneous squamous cell carcinoma (cSCC) is the second most prevalent form of skin cancer, showing a rapid increasing incidence worldwide. Although most cSCC can be cured by surgery, a sizeable number of cases are diagnosed at advanced stages, with local invasion and distant metastatic l...
Autores principales: | Quadri, Marika, Tiso, Natascia, Musmeci, Francesco, Morasso, Maria I., Brooks, Stephen R., Bonetti, Luca Reggiani, Panini, Rossana, Lotti, Roberta, Marconi, Alessandra, Pincelli, Carlo, Palazzo, Elisabetta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339543/ https://www.ncbi.nlm.nih.gov/pubmed/37443031 http://dx.doi.org/10.1186/s13046-023-02737-7 |
Ejemplares similares
-
Do DLX3 and CD271 Protect Human Keratinocytes from Squamous Tumor Development?
por: Palazzo, Elisabetta, et al.
Publicado: (2019) -
Isolation of an “Early” Transit Amplifying Keratinocyte Population in Human Epidermis: A Role for the Low Affinity Neurotrophin Receptor CD271
por: Lotti, Roberta, et al.
Publicado: (2022) -
Molecular Approach to Cutaneous Squamous Cell Carcinoma: From Pathways to Therapy
por: Palazzo, Elisabetta, et al.
Publicado: (2020) -
Survivin Modulates Squamous Cell Carcinoma-Derived Stem-Like Cell Proliferation, Viability and Tumor Formation in Vivo
por: Lotti, Roberta, et al.
Publicado: (2016) -
Specific Activation of the CD271 Intracellular Domain in Combination with Chemotherapy or Targeted Therapy Inhibits Melanoma Progression
por: Saltari, Annalisa, et al.
Publicado: (2021)